What question did this study set out to answer?

To establish and evaluate a refined clinical risk score for acute graft-versus-host disease at the onset of systemic steroid therapy to better predict therapeutic response and survival outcomes.

January 10, 2015Biology of Blood and Marrow TransplantationOpen Access

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality

View Full Paper

Ask AI

Bookmark

Authors

MMMargaret L. MacMillan MRMarie Robin AHAndrew C. Harris

Discussion

Member takes

Overview

Cohort study reveals a refined risk score stratifies treatment response and mortality in acute graft-versus-host disease, highlighting targeted clinical trial pathways.

Key Points

To establish and evaluate a refined clinical risk score for acute graft-versus-host disease at the onset of systemic steroid therapy to better predict therapeutic response and survival outcomes.
Assessed clinical stage and disease grade at the start of systemic steroid treatment in a cohort of 1,723 patients.
Used recursive partitioning, clinical grouping, and descriptive statistics to classify patients into high-risk (n=269) and standard-risk (n=1,454) acute graft-versus-host disease based on initial organ involvement and severity.
Day-28 overall response rates were significantly lower in high-risk patients compared with standard-risk patients (44% [95% CI, 38% to 50%] vs 68% [95% CI, 66% to 70%]; OR 0.3; 95% CI, 0.2 to 0.4; P < .001).
High-risk status predicted increased overall mortality (RR 2.1; 95% CI, 1.7 to 2.6; P < .001) and higher transplant-related mortality (RR 2.5; 95% CI, 2.0 to 3.2; P < .001) relative to standard risk.

Cite This Study

MacMillan et al. (2015) studied this question.

synapsesocial.com/papers/6a1068182badbc352afff384 https://doi.org/10.1016/j.bbmt.2015.01.001

View Full Paper

Ask AI

Bookmark

January 10, 2015Biology of Blood and Marrow TransplantationOpen Access

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality

View Full Paper

Ask AI

Bookmark

Authors

MMMargaret L. MacMillan MRMarie Robin AHAndrew C. Harris

Discussion

Member takes

Overview

Cohort study reveals a refined risk score stratifies treatment response and mortality in acute graft-versus-host disease, highlighting targeted clinical trial pathways.

Key Points

To establish and evaluate a refined clinical risk score for acute graft-versus-host disease at the onset of systemic steroid therapy to better predict therapeutic response and survival outcomes.
Assessed clinical stage and disease grade at the start of systemic steroid treatment in a cohort of 1,723 patients.
Used recursive partitioning, clinical grouping, and descriptive statistics to classify patients into high-risk (n=269) and standard-risk (n=1,454) acute graft-versus-host disease based on initial organ involvement and severity.
Day-28 overall response rates were significantly lower in high-risk patients compared with standard-risk patients (44% [95% CI, 38% to 50%] vs 68% [95% CI, 66% to 70%]; OR 0.3; 95% CI, 0.2 to 0.4; P < .001).
High-risk status predicted increased overall mortality (RR 2.1; 95% CI, 1.7 to 2.6; P < .001) and higher transplant-related mortality (RR 2.5; 95% CI, 2.0 to 3.2; P < .001) relative to standard risk.

Cite This Study

MacMillan et al. (2015) studied this question.

synapsesocial.com/papers/6a1068182badbc352afff384 https://doi.org/10.1016/j.bbmt.2015.01.001

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark